在初级扩散性慢性鼻炎患者中,在多现型中用mepolizumab治疗的真实世界的鼻结局
Nitish Kumar1, Evani Patel2, Michael J Marino1
1Department of Otorhinolaryngology - Head and Neck Surgery, Mayo Clinic, Phoenix, AZ, United States.
Frontiers in immunology
|February 20, 2026
概括
梅波利祖马布在慢性鼻炎 (CRS) 患者中有效降低了埃索诺菲尔和CT扫描得分. 症状的改善有所不同,这表明针对CRS表型的个性化治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 梅波利祖马布通过阻断IL-5来准2型埃索诺菲尔炎症.
- 对于初级扩散性CRS和没有鼻的CRS (CRSsNP) 中的mepolizumab,现实世界数据有限.
- 这项研究评估了mepolizumab在现实世界的扩散性CRS患者中的有效性,无论鼻的息肉状况如何.
研究的目的:
- 评估梅波利祖马布在初级扩散CRS中的实际有效性.
- 分析不同CRS表型 (CRSwNP与CRSsNP) 的结果.
- 评估先前内镜外科手术 (ESS) 对梅波利祖马布治疗结果的影响.
主要方法:
- 对277名患有原发性扩散性CRS的成年患者进行了回顾性分析,这些患者接受了梅波利祖马布治疗6个月以上.
- 测量结果包括血清乙酸细胞计数,隆德-麦凯CT得分,隆德-肯尼迪内镜得分和SNOT-22症状得分.
- 根据CRS表型和之前的ESS病史进行了亚组分析;记录了生物切换和停药.
主要成果:
- 梅波利祖马布在所有亚组显著降低了血清乙氨基和隆德-麦凯CT得分 (p<0.001).
- 在SNOT-22和内镜评分的改善是温和和不一致的.
- 在治疗期间,CRSwNP患者出现ESS的可能性更高,但与CRSsNP相比,治疗后第一次ESS的时间更长.
结论:
- 梅波利祖马布在初级扩散性CRS中有效降低了埃索诺菲利亚和放射性疾病,而不管表型或之前的手术.
- 可变的症状改善突出显示了患者对IL-5阻塞反应的异质性.
- 这些发现支持内型驱动的生物疗法,可能有利于精选的CRSsNP患者.
相关概念视频
Drugs Used in Upper Respiratory Disorders: Overview
725
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
725
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Epistaxis
626
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
626
Drugs Used in Lower Respiratory Disorders: Overview
1.2K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.2K


